Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Visual and refractive outcome of small incision lenticule extraction laser vision correction

Poster Details

First Author: R.Morris UK

Co Author(s):    J. Dermott   J. Bhatt   C. O'Donnell   A. Hartwig           

Abstract Details

Purpose:

To compare the refractive and visual outcome after Small Incision Lenticule Extraction laser vision correction (Zeiss)

Setting:

Optegra Central London Eye hospital, London, UK

Methods:

The study population consisted of 71 eyes of 37 patients (22 male). Patients were treated by one of three surgeons. Mean age was 34 �Â�± 8 years, (range from 22 to 58 years). All underwent SMILE surgery using Zeiss Visumax Laser System (Carl Zeiss Meditec, Germany) at a private eye hospital in the UK. Unaided and best corrected distance and near monocular and binocular visual acuity (UDVA, UNVA) were reported up to the three month stage, along with spherical equivalent refraction and patient-reported outcomes. Enhanced eyes and those with a non-zero target were excluded from monocular acuity analysis.

Results:

Post-operative spherical equivalent at 3 months was -0.19 �Â�± 0.45 D with 98% of all eyes within �Â�±1.00D and 88% of all eyes within �Â�±0.50D of target. The mean unaided distance visual acuity (UDVA) post-operatively was -0.07 �Â�± 0.11 LogMAR with 98% of zero-target eyes achieving unaided acuity of at least 20/40 and 89% achieving at least 20/20. Mean post-operative CDVA was -0.10 �Â�± 0.09 LogMAR. Binocular UNVA of N5 or better was achieved by all eyes. All the patients completing an electronic satisfaction survey reported being either very satisfied or satisfied with the outcome of their surgery.

Conclusions:

This early data demonstrated good results in terms of post-operative refraction and unaided monocular and binocular distance and near visual acuity. Further research is required in order to appreciate the longer-term stability of the treatment.

Financial Disclosure:

NONE

Back to Poster listing